20 reports

  • 7. Autoimmune Disease Diagnostics Market - Company Profiles

Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chroni

  • Diagnostics
  • World
  • Market Size
  • bioMerieux S.A.
  • Roche Group

Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chroni

  • Diagnostics
  • World
  • Forecast
  • Alere Inc.
  • Danaher Corporation

The brief outpatient treatments allow for little to no SHOWCASE PRESENTATION DETAILS Title: " Advances in Neuromodulation for the Treatment of Neuropsychiatric Conditions" Date: Saturday, October ##th Time: ##:## - ##:## p. m.

  • Depression
  • Mental Health
  • Personality Disorder
  • United States
  • Brainsway Ltd.
  • Market positioning of vendors

IT ALSO OFFERS NEUROMODULATION DEVICES FOR THE MANAGEMENT OF CHRONIC PAIN AND MOVEMENT DISORDERS.

  • Diagnostics
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • COMPETITIVE ANALYSIS

This segment also offers neuromodulation devices for the management of movement disorders and chronic pain.

  • Diagnostics
  • World
  • Ascensia Diabetes Care
  • DexCom, Inc.
  • Medtronic, Inc.
  • C. DIFFICILE TOX A/B
  • Staphylococcus

DEVICE-ASSOCIATED INFECTIONS ALSO CAUSE GREAT ECONOMIC BURDEN.

  • Diagnostics
  • World
  • Market Size
  • Danaher Corporation
  • QIAGEN N.V.

Notes Recent Development section covers news posted during last one year GlobalData considers regulatory approved (Approved and Issued) products as pipeline in case products are yet to launch in the market.

  • Diagnostics
  • Electrodiagnosis
  • Neurological Monitoring
  • United States
  • Product Initiative

Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chroni

  • Diagnostics
  • North America
  • United States
  • bioMerieux S.A.
  • Danaher Corporation
  • THREATS

Cardiovascular and neuromodulation products segment offers electrophysiology, cardiac rhythm management, vascular, heart failure, and structural heart devices for the treatment of cardiovascular diseases and the neuromodulation segment offers neuromodulation impla

  • Diagnostics
  • World
  • Forecast
  • Market Size
  • Roche Group

Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chroni

  • Diagnostics
  • East Asia
  • Japan
  • Abbott Laboratories, Inc.
  • Bio-Rad Laboratories, Inc.
  • FORECAST

IMPLANTATION There are three SCS device types: ##.

  • Diagnostics
  • Personality Disorder
  • World
  • Boston Scientific Corporation
  • Cyberonics, Inc.

Alecxih served as Vice President of Worldwide Sales at Nevro, where he led the high-growth neuromodulation device company' s commercial efforts across multiple geographies.

  • Biopsy
  • Diagnostic Imaging
  • Diagnostics
  • United States
  • Company
  • 15.1.4 Key Strategies
  • 15 KEY COMPANY PROFILES

This segment also offers neuromodulation devices for the management of movement disorders and chronic pain.

  • Diagnostics
  • North America
  • United States
  • Alere Inc.
  • Danaher Corporation

The ENT devices segment reported two equity offerings worth USD##. ##m, one debt offering worth USD##m, one VC deal worth USD##m, and one partnership in February 2018.

  • Diagnostics
  • Medical Device
  • World
  • Company
  • Deals & Alliance

STIMWAVE' S DEVICES USE WIRELESS PAIN RELIEF® TECHNOLOGY AND ARE ## PERCENT SMALLER THAN ANY OTHER NEUROMODULATION DEVICE ON THE MARKET.

  • Clinical Chemistry
  • Diagnostics
  • In Vitro Diagnostic Reagent
  • Personality Disorder
  • Point Of Care Testing

STIMWAVE' S DEVICES USE WIRELESS PAIN RELIEF® TECHNOLOGY AND ARE ## PERCENT SMALLER THAN ANY OTHER NEUROMODULATION DEVICE ON THE MARKET.

  • Diagnostics
  • Hospital
  • In Vitro Diagnostic Reagent
  • Personality Disorder
  • Point Of Care Testing

Intelect Medical is developing advanced neuromodulation technologies for deep brain stimulation (DBS) therapy.

  • Diagnostics
  • Personality Disorder
  • United States
  • B. Braun Melsungen AG
  • Becton Property Group

Intelect Medical is developing advanced neuromodulation technologies for deep brain stimulation (DBS) therapy.

  • Diagnostics
  • Personality Disorder
  • United States
  • World
  • M&A

The neurology devices market recorded five VC deals worth USD##. ##m, two partnerships, one private equity deal worth USD##m, one debt offering worth USD##m, and one equity offering in July 2017.

  • Diagnostics
  • Medical Device
  • World
  • Company
  • Deals & Alliance

Notes Recent Development section covers news posted during last one year GlobalData considers regulatory approved (Approved and Issued) products as pipeline in case products are yet to launch in the market.

  • Diagnostics
  • Electrodiagnosis
  • Neurological Monitoring
  • United States
  • Product Initiative